Hurry! Sale Price Ends Tonight!
Workflow

Clinical trials on Covid-19 patients with Colchicine

Clinical trials on Covid-19 patients with Colchicine

  • (CSIR), and Laxai Life Sciences Pvt. Ltd. Hyderabad, has been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in the improvement of clinical outcomes during the treatment of COVID-19 patients.
  • Colchicine is a medication used to treat gout and Behçet's disease.
  • Dr Ram Upadhayay, CEO, Laxai informed, that the enrollment of patients has already begun at multiple sites across India and the trial is likely to be completed in the next 8-10 weeks.

  • Recent clinical studies have reported in leading medical journals about colchicine being associated with a significant reduction in the rates of recurrent pericarditis, post-pericardiotomy syndrome, and peri-procedural atrial fibrillation following cardiac surgery and atrial fibrillation ablation.

  • Colchicine is a medication used to treat gout and Behçet's disease.
  • In gout, it is less preferred to NSAIDs or steroids.
  • Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.
  • Colchicine has a narrow therapeutic index and overdosing is, therefore, a significant risk.
  • Common side effects of colchicine include gastrointestinal upset, particularly at high doses.
  • Severe side effects may include low blood cells and rhabdomyolysis, and the medication can be deadly in overdose.

Categories